Reposted by KharofaJ
Pancreatic cancer–restricted cryptic antigens are targets for T cell recognition
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Pancreatic cancer–restricted cryptic antigens are targets for T cell recognition
Translation of the noncoding genome in cancer can generate cryptic (noncanonical) peptides capable of presentation by human leukocyte antigen class I (HLA-I); however, the cancer specificity and immun...
www.science.org
May 9, 2025 at 12:53 AM
Pancreatic cancer–restricted cryptic antigens are targets for T cell recognition
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Reposted by KharofaJ
I’m SO delighted to finally see first STAR-TREC data reported 🤩 #ESTRO25
Short course RT vs chemorad for organ preservation in early stage rectal cancer
61% vs 80% TME-free survival at 12 months ➡️ More organ preservation with long-course chemorad!
#radonc #rectalcancer
Short course RT vs chemorad for organ preservation in early stage rectal cancer
61% vs 80% TME-free survival at 12 months ➡️ More organ preservation with long-course chemorad!
#radonc #rectalcancer
May 4, 2025 at 10:02 AM
I’m SO delighted to finally see first STAR-TREC data reported 🤩 #ESTRO25
Short course RT vs chemorad for organ preservation in early stage rectal cancer
61% vs 80% TME-free survival at 12 months ➡️ More organ preservation with long-course chemorad!
#radonc #rectalcancer
Short course RT vs chemorad for organ preservation in early stage rectal cancer
61% vs 80% TME-free survival at 12 months ➡️ More organ preservation with long-course chemorad!
#radonc #rectalcancer
Reposted by KharofaJ
New @thelancetoncol.bsky.social - Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trial
www.thelancet.com/journals/lan...
#Gastrosky #Oncsky #Medsky #ESTRO25 @oncoalert.bsky.social
www.thelancet.com/journals/lan...
#Gastrosky #Oncsky #Medsky #ESTRO25 @oncoalert.bsky.social
Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trial
Good 6-month complete clinical responses rates were seen in both groups. Early results
suggest rd-IMRT is well tolerated with oncological outcomes maintained. 3-year locoregional
failure rates are awa...
www.thelancet.com
May 4, 2025 at 11:21 AM
New @thelancetoncol.bsky.social - Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trial
www.thelancet.com/journals/lan...
#Gastrosky #Oncsky #Medsky #ESTRO25 @oncoalert.bsky.social
www.thelancet.com/journals/lan...
#Gastrosky #Oncsky #Medsky #ESTRO25 @oncoalert.bsky.social
Reposted by KharofaJ
PLATO ACT 4 results for dose de-escalation in early-stage anal cancer are out! Prof Sebag-Montefiore presents on the plenary stage at #ESTRO24
3-year locoregional failure 16.4% for standard dose IMRT vs 12.4% reduced dose IMRT
Primary endpoint is met! Reduced dose IMRT is safe & effective
#radonc
3-year locoregional failure 16.4% for standard dose IMRT vs 12.4% reduced dose IMRT
Primary endpoint is met! Reduced dose IMRT is safe & effective
#radonc
May 4, 2025 at 9:50 AM
Reposted by KharofaJ
Reposted by KharofaJ
Yesterday, the House passed an FY25 budget bill that slashes funding to the Pancreatic Cancer Research Program by 57%.
Research for pancreatic cancer is already woefully underfunded, and now the only program exclusively funding pancreatic cancer research is one step closer to devastating cuts.
Research for pancreatic cancer is already woefully underfunded, and now the only program exclusively funding pancreatic cancer research is one step closer to devastating cuts.
March 13, 2025 at 12:20 AM
Yesterday, the House passed an FY25 budget bill that slashes funding to the Pancreatic Cancer Research Program by 57%.
Research for pancreatic cancer is already woefully underfunded, and now the only program exclusively funding pancreatic cancer research is one step closer to devastating cuts.
Research for pancreatic cancer is already woefully underfunded, and now the only program exclusively funding pancreatic cancer research is one step closer to devastating cuts.
Reposted by KharofaJ
Big health breakthrough: a protein from tardigrades can now protect human cells from radiation.
That’s going to lead to better cancer therapies.
That’s going to lead to better cancer therapies.
Radioprotection of healthy tissue via nanoparticle-delivered mRNA encoding for a damage-suppressor protein found in tardigrades - Nature Biomedical Engineering
Radiation-therapy-induced DNA damage in oral and rectal epithelial cells can be reduced via the nanoparticle-mediated local delivery of messenger RNA encoding for a damage-suppressor protein found in ...
www.nature.com
March 5, 2025 at 8:58 PM
Big health breakthrough: a protein from tardigrades can now protect human cells from radiation.
That’s going to lead to better cancer therapies.
That’s going to lead to better cancer therapies.
Reposted by KharofaJ
Hello Bluesky! Let’s try a first post…here’s my latest story for @naturebiotech.bsky.social on @vertexpharma.bsky.social non-opioid pain killer and next-gen NaV1.8 inhibitors in the pipeline rdcu.be/ealj0
Vertex’s opioid-free drug for acute pain wins FDA approval
Nature Biotechnology - Society, patients and clinicians welcome a much-needed non-opioid pain medication. Vertex’s first-in-class analgesic Journavx could soon be followed by a new generation...
rdcu.be
February 18, 2025 at 1:03 PM
Hello Bluesky! Let’s try a first post…here’s my latest story for @naturebiotech.bsky.social on @vertexpharma.bsky.social non-opioid pain killer and next-gen NaV1.8 inhibitors in the pipeline rdcu.be/ealj0
Reposted by KharofaJ
New essay on NIH and indirect costs:
goodscience.substack.com/p/indirect-c...
goodscience.substack.com/p/indirect-c...
Indirect Costs at NIH . . .
I wasn’t planning on spending part of a Saturday writing about cost accounting principles and the like, but NIH-world was hit with a doozy of a policy announcement on Friday night:
goodscience.substack.com
February 8, 2025 at 11:53 PM
New essay on NIH and indirect costs:
goodscience.substack.com/p/indirect-c...
goodscience.substack.com/p/indirect-c...
Reposted by KharofaJ
ctDNA Status Is Prognostic for DFS With Celecoxib in Stage III Resected Colon Cancer @danafarber.bsky.social @ascocancer.bsky.social #GI25 #crcsm #oncology www.onclive.com/view/ctdna-s...
ctDNA Status Is Prognostic for DFS With Celecoxib in Stage III Resected Colon Cancer
ctDNA positivity was associated with worse DFS overall but significantly better DFS with celecoxib vs placebo in stage III resected colon cancer.
www.onclive.com
January 25, 2025 at 3:09 PM
ctDNA Status Is Prognostic for DFS With Celecoxib in Stage III Resected Colon Cancer @danafarber.bsky.social @ascocancer.bsky.social #GI25 #crcsm #oncology www.onclive.com/view/ctdna-s...
Reposted by KharofaJ
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial @JAMAOnc
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma
This phase 3 randomized clinical trial evaluates whether stereotactic body radiation therapy improves outcomes in patients with locally advanced hepatocellular carcinoma compared with sorafenib alone.
jamanetwork.com
December 20, 2024 at 11:12 PM
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial @JAMAOnc
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Reposted by KharofaJ
It is with great sadness that we mourn our cherished friend and colleague Felix Feng, MD. Felix was a distinguished physician-scientist and beloved at @ucsfhealth.bsky.social. His vision, dedication, and commitment inspired colleagues, peers everywhere, and patients. cancer.ucsf.edu/in-memoriam-...
December 14, 2024 at 12:00 AM
It is with great sadness that we mourn our cherished friend and colleague Felix Feng, MD. Felix was a distinguished physician-scientist and beloved at @ucsfhealth.bsky.social. His vision, dedication, and commitment inspired colleagues, peers everywhere, and patients. cancer.ucsf.edu/in-memoriam-...
Reposted by KharofaJ
For those who haven’t seen it yet, here is a started pack for those interested in pancreatic cancer:
go.bsky.app/2FHVVL6
go.bsky.app/2FHVVL6
December 2, 2024 at 5:40 PM
For those who haven’t seen it yet, here is a started pack for those interested in pancreatic cancer:
go.bsky.app/2FHVVL6
go.bsky.app/2FHVVL6